MEA Vaccine Contract Manufacturing Market

MEA Vaccine Contract Manufacturing Market Size (2023 to 2028)

The size of the Vaccine contract manufacturing Market in the MEA was about USD 95.88 million in 2023. It is expected to rise at a CAGR of 8.8% to reach approximately USD 146.18 million by 2028.

Increasing government support for the development of healthcare infrastructure in some of the developing countries of MEA is one major factor propelling the growth vaccine contract manufacturing market. Growing demand for the invention of vaccines and contract manufacturing are escalating market growth. Different bacterial and viral infections are regularly increasing, augmenting market demand. Expansion of population base amid the developing countries and growing support from the public and private organizations impels market growth. Escalating urbanization and industrialization is likely to boost the market. Mounting massive demand from different the Middle East & African countries for the launch of novel vaccines is to enlarge the market portfolio.

The vaccination cost is prohibitive, which is one of the major factors hindering the market growth. Strict rules and guidelines and lengthy approval procedures by government organizations for new products hamper the market demand. 

This research report on the Middle East and Africa vaccine contract manufacturing market has been segmented and sub-segmented into the following categories:

By Service Type:

• Bulk Product
• Fill Finish

By Product Type:

• Single Vaccine
  • Influenza Virus
  • Ebola Virus
  • Chickenpox
  • Tetanus
  • Tuberculosis
  • Polio
  • Smallpox
  • Others
• Combination Type

By Vaccine Type:

• Inactivated Vaccines
• Conjugate Vaccines
• Live Attenuated Vaccines
• Toxoid Vaccines
• Recombinant Vector Vaccines
• Subunit Vaccines
• Synthetic Vaccines

By Country:

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

Geographically, the Halal vaccine market is a vast untapped area in this region. Also, because of various policy changes in regional governments, a steady increase is expected regarding this market. Middle East & Africa are expected to have a sluggish growth rate in the vaccine coverage market. Surging unmet needs for vaccination, the country's government policies and international bodies like the World Health Organization (WHO) are escalating the market demand. South Africa is leading the vaccine contract manufacturing market with the largest share. Huge funds and investments from International key players and increasing support from philanthropy organizations, including few vaccines among the national vaccine of many countries in MEA, are likely to escalate the market growth. International healthcare organizations taking part in different vaccination programs are expected to influence the market growth in vaccine contract manufacturing. Moreover, advantages associated with the cost in infrastructure, operational benefits, and reduced time are propelling the market growth. UAE, Saudi Arabia, KSA, and the rest of MEA are projected to a substantial increase in the vaccine contract manufacturing market.

Major manufacturing companies in the Middle East and Africa vaccine contract manufacturing market are GSK, SPIMANCO, Pfizer, Tabuk, Novartis, Jamjoom, Astra, Julphar, MSD, and Janssen.